Prelude Corporation (PreludeDx(r)), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreast(tm), a novel multi-omic biosignature developed to predict a woman’s 10-year risk of locoregional recurrence (LRR) and her individualized benefit from adjuvant radiation therapy (RT) following breast-conserving surgery.
